In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nippon Boehringer Ingelheim Co. Ltd.

Division of Boehringer Ingelheim International GmbH

Latest From Nippon Boehringer Ingelheim Co. Ltd.

Asia On The Move: Beijing Tiantan Executives Resign Amid Vaccine Deaths

The new year brings in new faces as Takeda ushered in its first CIO and Pfizer divided its business unit in South Korea, following a global restructuring plan. Following infant deaths in China, vaccine manufacturer Beijing Tiantan saw three executives depart; personnel changes also took place at Shire and EFPIA in Japan.

BioPharmaceutical China

MHLW Raises Bar For Generic Usage In Japan To New Heights

On the heels of missing its March 2013 target for generic usage, Japan’s Ministry of Health, Labor and Welfare issues far-reaching mandate to increase generic prescription rates.

BioPharmaceutical Japan

Biopharma Quarterly Statistics Q1 2010

In Vivo presents another quarterly review of pharmaceutical/biotechnology dealmaking - for the first quarter of 2010. Our data come from Elsevier's Strategic Transactions. During the first quarter of 2010, biopharma companies raised $2.6 billion through 94 transactions, slightly better than last year's opening, but a decrease of 43% from Q4 2009. Early venture capital rounds were the most popular type of financings, followed closely by follow-on public offerings and private investments in public companies, but FOPOs clearly brought in the most money, $1.1 billion.With less than half the M&A deal volume of the previous quarter - however, about the same dollar figure - Q1 2010's 12 transactions brought in $7.1 billion.

Deals Shaping the Medical Industry (03/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Nippon Boehringer Ingelheim
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Boehringer Ingelheim International GmbH
  • Senior Management
  • N. Motohashi, Chmn.
    Tsuneki Kawabata, Pres.
  • Contact Info
  • Nippon Boehringer Ingelheim Co. Ltd.
    Phone: (81) 03-6417-2145
    ThinkPark Tower, Shinagawa-ku
    211 Ohsaki
    Tokyo, 141-6017